Last reviewed · How we verify
NCT06043947: SURVIMON
Survival Monitoring in Russian Cancer Registries
trial in Melanoma in 100,000 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2024
Quick facts
| Lead sponsor | N.N. Petrov National Medical Research Center of Oncology |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 100,000 |
| Start date | 1 August 2023 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Russia |
Conditions studied
- Melanoma — all drugs for Melanoma →
- Breast Cancer — all drugs for Breast Cancer →
- Oncology — all drugs for Oncology →
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
N.N. Petrov National Medical Research Center of Oncology — full company profile →
Who can join
Adults 0 to 100, any sex, with Melanoma or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data. The data from the population-based cancer registries of the Northwestern regions of Russia will be used to assess net and cause-specific survival trends.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06043947
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07224425 — A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07225036 — Promoting Immunotherapy Efficacy With Low-Dose Liver RT · NA · recruiting
- NCT07379138 — Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improve · NA · recruiting
Other N.N. Petrov National Medical Research Center of Oncology trials
Trials by the same sponsor.
- NCT06418789 — High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors · Phase 2 · recruiting
- NCT06133699 — Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors · NA · unknown
- NCT06229340 — Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations · Phase 2 · recruiting
- NCT05468827 — ICG Fluorescence Guided Lymph Node Mapping for Determination of Bowel Resection Margins in Colon Cancer · NA · completed
- NCT06299852 — Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06043947 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by N.N. Petrov National Medical Research Center of Oncology
- Last refreshed: 1 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06043947.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing